Product information and disease descriptionPlace of product in therapyApproaches to treatment
Place in treatment, anticipated use, and care setting
2 evidence topics · 4 sources
Summary
QTORIN rapamycin has been studied as a self-administered topical treatment. SELVA required clinically confirmed superficial/cutaneous microcystic lymphatic malformations and excluded complicated vascular anomalies with severe systemic symptoms requiring systemic therapy. The sponsor describes the diagnosed population as concentrated in vascular anomaly centers. The report does not establish an approved treatment sequence or an approved prescribing setting for this investigational formulation.